Observational studyNeurology2024
Association of Changes in Cerebral and Hypothalamic Structure With Sleep Dysfunction in Patients With Genetic Frontotemporal Dementia.
Abstract readMulticenter StudyObservational Study
In one paragraph
Observational study in Neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Clinical features of sleep disturbance in temporal lobe variants of frontotemporal dementia.Journal of neurology · 2026Article
- Continuous At-Home Monitoring of Nighttime Bed Behavior in Frontotemporal Dementia.Neurology open access · 2026Article
- Sleep Disorders in Neurodegenerative Diseases with Dementia: A Comprehensive Review.Journal of clinical medicine · 2025Review
- Disparate and shared transcriptomic signatures associated with cortical atrophy in genetic behavioral variant frontotemporal degeneration.Molecular neurodegeneration · 2025Article
- Functional Connectivity Alterations Associated with COVID-19-Related Sleep Problems: A Longitudinal Resting-State fMRI Study.Nature and science of sleep · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
P Tristin BestFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.
John C Van SwietenFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0001-6278-6844
Lize Corrine JiskootFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0002-1120-1858
Fermin MorenoFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0001-5200-3164
Raquel Sánchez-ValleFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0001-7750-896X
Robert LaforceFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0002-2031-490X
Caroline GraffFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0002-9949-2951
Mario MasellisFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0002-6244-2096
Carmela TartagliaFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.
James B RoweFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0001-7216-8679
Barbara BorroniFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0001-9340-9814
Elizabeth FingerFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0003-4461-7427
Matthis SynofzikFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0002-2280-7273
Daniela GalimbertiFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0002-9284-5953
Rik VandenbergheFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0001-6237-2502
Alexandre de MendonçaFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0002-0488-1453
Christopher ButlerFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0002-7502-9284
Alexander GerhardFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0002-8071-6062
Isabelle Le BerFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0002-2508-5181
Pietro TiraboschiFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0002-2171-1720
Isabel SantanaFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0002-8114-9434
Florence PasquierFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0001-9880-9788
Johannes LevinFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0001-5092-4306
Markus OttoFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0003-4273-4267
Sandro SorbiFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0002-0380-6670
Harro SeelaarFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0003-1989-7527
Arabella BouziguesFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0002-0267-8590
David M CashFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0001-7833-616X
Lucy Louise RussellFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0001-5023-5893
Martina BocchettaFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.
Jonathan Daniel RohrerFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0002-6155-8417
Gabriel A DevenyiFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.
Mallar ChakravartyFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.
Simon DucharmeFrom the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.ORCID 0000-0002-7309-1113
Genetic Frontotemporal Dementia Initiative (GENFI)From the Integrated Program in Neuroscience (P.T.B.), McGill, Montréal, Canada; Department of Neurology (J.C.V.S., H.S., L.C.J.), Erasmus Medical Centre, Rotterdam, Netherlands; Department of Neurology (F.M.), Donostia Universitary Hospital, San Sebastián, Spain; Institut D'Investigacións Biomèdiques August Pi I Sunyer (R.S.-V.), University of Barcelona, Spain; Faculté de Médecine (R.L.), Université Laval, Québec City, Canada; Department of Neurobiology (C.G.), Karolinska Institutet, Solna, Sweden; Sunnybrook Research Institute (M.M.), Toronto, Canada; Tanz Centre for Research in Neurodegenerative Diseases (C.T.), University of Toronto, Canada; Department of Clinical Neurosciences (J.B.R.), University of Cambridge, United Kingdom; Department of Clinical and Experimental Sciences (B.B.), University of Brescia, Italy; Department of Clinical Neurological Sciences (E.F.), University of Western Ontario, London, Canada; Hertie-Institute for Clinical Brain Research and Center of Neurology (M.S.), University of Tübingen, Germany; Neurology (D.G.), University of Milan, Italy; Department of Neurosciences (R.V.), KU Leuven, Belgium; Faculty of Medicine (A.M.), University of Lisbon, Portugal; Nuffield Department of Clinical Neurosciences (C.B.), University of Oxford, United Kingdom; Wolfson Molecular Imaging Centre (A.G.), University of Manchester, United Kingdom; Institut du Cerveau-ICM (I.L.B.), Hôpital Pitié-Salpêtrière, Paris, France; 31Fondazione IRCCS (P.T.), Istituto Neurologico Carlo Besta, Milan, Italy; Faculty of Medicine (I.S.), University of Coimbra, Portugal; Department of Neurology (F.P.), Université Lille, France; Department of Neurology (J.L.), Ludwig-Maximilians Universität München, Munich, Germany; Department of Neurology (M.O.), University of Ulm, Germany; Department of Neurofarba (S.S.), University of Florence, Italy; Department of Neurodegenerative Disease (A.B., D.M.C., L.L.R., M.B., J.D.R.), University College London, United Kingdom; and Department of Psychiatry (G.A.D., M.C., S.D.), McGill University, Montréal, Canada.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesSleep dysfunction is common in patients with neurodegenerative disorders; however, its neural underpinnings remain poorly characterized in genetic frontotemporal dementia (FTD). Hypothalamic nuclei important for sleep regulation may be related to this dysfunction. Thus, we examined changes in hypothalamic structure across the lifespan in patients with genetic FTD and whether these changes related to sleep dysfunction.
methodsData from the observational multisite Genetic Frontotemporal Dementia Initiative (GENFI) study were used. GENFI participants were adult members of a family with known pathogenic variants in the microtubule-associated protein tau (MAPT) or progranulin (GRN) genes or an expansion in the chromosome 9 open reading frame 72 (C9orf72) gene. Family members without a pathogenic variant served as controls. GENFI participants were followed annually, with up to 7 visits, and underwent clinical characterization, neuropsychological testing, biological sampling, and brain MRI. For our analyses, participants were included if they had at least 1 T1-weighted structural MRI scan available. Linear mixed-effect models were used to examine changes in sleep dysfunction, measured using the Cambridge Behavioural Inventory-Revised sleep subscale, volumetric changes in hypothalamic regions, and the associations between cortical and hypothalamic atrophy and sleep dysfunction.
resultsParticipants included 491 adults with pathogenic genetic variants of FTD (27.9% symptomatic; median age: 49.4 years, 56.4% DISCUSSION: These findings suggest that sleep dysfunction in patients with genetic FTD may be attributable to atrophy in sleep-relevant hypothalamic subunits, with the most severe and consistent deficits observed in MAPT carriers. While biologically plausible, our statistical approach cannot confirm a causal link between atrophy and sleep disturbances.
Indexed as
Frontotemporal DementiaHypothalamusMagnetic Resonance ImagingSleep Wake Disorderstau ProteinsAdultAgedAtrophyC9orf72 ProteinCerebral CortexFemaleHumansMaleMiddle AgedProgranulinsC9orf72 ProteinC9orf72 protein, humanGRN protein, humanMAPT protein, humanProgranulinstau Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.